We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > IBI305

News List

Study Results of Sintilimab in Combination with Bevacizumab Biosimilar IBI305 for the First-Line Treatment of Hepatocellular Carcinoma Published in The Lancet Oncology prnasia
June 21, 2021
Innovent Biologics, Inc. today announced that data from the ORIENT-32 study have been published in The Lancet Oncology.
Coherus signs in-licensing agreement for Avastin biosimilar pharmaceutical-technology
January 15, 2020
Coherus BioSciences has signed an in-licensing agreement to acquire commercial rights of Innovent Biologics’ biosimilar candidate to Avastin (bevacizumab) (IBI305) in the US and Canada.
Innovent declares positive result of IBI305, biosimilar to Avastin biospectrumasia
December 17, 2018
“Anti-angiogenic drugs are effective anti-tumor treatments, but as of yet there are no approved bevacizumab biosimilars in China.